The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index, and 2 are not checked yet.
Cross-reactive memory T cells and herd immunity to SARS-CoV-2
Open accessAbstract
Immunity is a multifaceted phenomenon. For T cell-mediated memory responses to SARS-CoV-2, it is relevant to consider their impact both on COVID-19 disease severity and on viral spread in a population. Here, we reflect on the immunological and epidemiological aspects and implications of pre-existing cross-reactive immune memory to SARS-CoV-2, which largely originates from previous exposure to circulating common cold coronaviruses. We propose four immunological scenarios for the impact of cross-reactive CD4+ memory T cells on COVID-19 severity and viral transmission. For each scenario, we discuss its implications for the dynamics of herd immunity and on projections of the global impact of SARS-CoV-2 on the human population, and assess its plausibility. In sum, we argue that key potential impacts of cross-reactive T cell memory are already incorporated into epidemiological models based on data of transmission dynamics, particularly with regard to their implications for herd immunity. The implications of immunological processes on other aspects of SARS-CoV-2 epidemiology are worthy of future study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“at least some individuals are low or negative to commercial IgG assays, while retaining detectable SARS-CoV-2 CD4+ T cells. Current estimates are these individuals represent 1%–10% of PCR-confirmed SARS-CoV-2 infections (Gudbjartsson et al., 2020; Lipsitch et al., 2020; Nelde et al., 2021; Schwarzkopf et al., 2021; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Lipsitch et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [111]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [111]
In the citing paper
“It is possible that cross-protection via adaptive immune responses against endemic coronaviruses might be in part responsible for mild disease courses in younger individuals (Lipsitch et al., 2020).”
From COVID-19 and the human innate immune system (2021) · cites this paper as Lipsitch et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Héry-Arnaud, G., Berre, R. L., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 5,008
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Self-citationClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611
Self-citationSuperspreading and the effect of individual variation on disease emergence
Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E., & Getz, W. M. (2005) · Nature · doi:10.1038/nature04153 · Cited by 2,514
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790
Self-citationRobust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Cited by
Sorted by citations
Items 101–200 of 259
SARS-CoV-2-specific T cell responses and immune regulation in infected pregnant women
Hsieh, L., Grifoni, A., Dave, H., Wang, J., Johnson, D., Zellner, J. A., Sidney, J., Chambers, C., & Franco, A. (2021) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2021.103464 · Cited by 18
Redox Homeostasis and Immune Alterations in Coronavirus Disease-19
Bellanti, F., Buglio, A. L., & Vendemiale, G. (2022) · Biology · doi:10.3390/biology11020159 · Cited by 18
The influence of time on the sensitivity of SARS-CoV-2 serological testing
Ortiz, A. T., Torrente, F. F., Twigg, A., Hatcher, J., Saso, A., Lam, T., Johnson, M., Wagstaffe, H. R., Dhillon, R., Mai, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-14351-2 · Cited by 17
Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens
Vojdani, A., Vojdani, E., Melgar, A. L., & Redd, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1003094 · Cited by 17
Systemic CD4 cytotoxic T cells improve protection against PRRSV-1 transplacental infection
Li, Y., Díaz, I., Martin-Valls, G. E., Beyersdorf, N., & Mateu, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020227 · Cited by 17
Solforosi, L., Costes, L. M. M., Tolboom, J. T. B. M., McMahan, K., Anioke, T., Hope, D. L., Murdza, T., Sciacca, M., Bouffard, E., Barrett, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37715-2 · Cited by 16
Human lung organoid modelling of tissue-resident antiviral T cell responses
Rathkey, J. K., Choi, S. S., van Unen, V., Zhang, H., Liu, M., Ding, J., Alwahabi, S., Santos, A. J. M., Mallajosyula, V. V. A., Chan, J. E., et al. (2026) · Nature · doi:10.1038/s41586-026-11114-1 · Cited by 17
Self-citationBecerra‐Artiles, A., Nanaware, P. P., Muneeruddin, K., Weaver, G. C., Shaffer, S. A., Calvo‐Calle, J. M., & Stern, L. J. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011032 · Cited by 18
Muñoz‐Ruiz, M., Llorian, M., D’Antuono, R., Pavlova, A., Mavrigiannaki, A. M., McKenzie, D. R., García-Cassani, B., Iannitto, M. L., Wu, Y., Dart, R., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.07.015 · Cited by 18
Hu, L., Deng, W., Ying, G., & Hong, H. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112297 · Cited by 17
Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities
Galani, I. E., & Andreakos, E. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101522 · Cited by 17
Pathak, S., Jolly, M. K., & Nandi, D. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1908058 · Cited by 15
Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers
Tosun, S. Y., Özdemir, H. Ö., Erdoğan, E., Yalbuzdağ, Ş. A., Aysın, M., Eşkut, N., Ortan, P., & Eşkut, B. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1999708 · Cited by 16
Riou, C., Schäfer, G., Bruyn, E. D., Goliath, R. T., Stek, C. J., Mou, H., Hung, D., Wilkinson, K. A., & Wilkinson, R. J. (2021) · European Respiratory Journal · doi:10.1183/13993003.00285-2021 · Cited by 17
Rose, J., & McCullough, P. A. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101011 · Cited by 18
RetractedToward superhuman SARS-CoV-2 immunity?
Burton, D. R., & Topol, E. J. (2020) · Nature Medicine · doi:10.1038/s41591-020-01180-x · Cited by 15
Quantifying T Cell Cross-Reactivity: Influenza and Coronaviruses
Gaevert, J. A., Duque, D. L., Lythe, G., Molina-Parı́s, C., & Thomas, P. G. (2021) · Viruses · doi:10.3390/v13091786 · Cited by 13
Immunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 14
Dan, J. M., Antunes, R. D. S., Grifoni, A., Weiskopf, D., Crotty, S., & Sette, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac310 · Cited by 16
Self-citationRabets, A., Bila, G., Grytsko, R., Samborskyy, M., Rebets, Y. V., Vari, S. G., Pagneux, Q., Barras, A., Boukherroub, R., Szunerits, S., et al. (2021) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-021-00607-8 · Cited by 13
Paniskaki, K., Konik, M., Anft, M., Meister, T. L., Marheinecke, C. S., Pfaender, S., Jäger, J., Krawczyk, A., Zettler, M., Dolff, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1031254 · Cited by 14
IFN‐γ+ cell response and IFN‐γ release concordance after in vitro SARS‐CoV‐2 stimulation
Vallejo, A., Vizcarra, P., Quereda, C., Moreno, A. M., Casado, J. L., & the CoVEX study group (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13636 · Cited by 22
Almazán, N. M., Rahbar, A., Carlsson, M., Hoffman, T., Kolstad, L., Rönnberg, B. J., Pantalone, M. R., Lewensohn‐Fuchs, I., Nauclér, A., Ohlin, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108441 · Cited by 17
The Immunopathobiology of SARS-CoV-2 Infection
Patel, M., Shahjin, F., Cohen, J. D., Hasan, M., Machhi, J., Chugh, H., Singh, S., Das, S., Kulkarni, T. A., Herskovitz, J., et al. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab035 · Cited by 15
Ogura, H., Gohda, J., Lu, X., Yamamoto, M., Takesue, Y., Son, A., Doi, S., Matsushita, K., Isobe, F., Fukuda, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34655-1 · Cited by 14
Deakin, C. T., Cornish, G. H., Ng, K. W., Faulkner, N., Bolland, W., Hope, J., Rosa, A., Harvey, R., Hussain, S., Earl, C. P., et al. (2021) · Med · doi:10.1016/j.medj.2021.08.001 · Cited by 12
Pacheco-Olvera, D. L., Remy-Hernández, S. S., García-Valeriano, M. G., Rivera-Hernández, T., & López-Macías, C. I. R. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.10.007 · Cited by 12
Natalini, A., Simonetti, S., Sher, C., D’Oro, U., Hayday, A., & Rosa, F. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214367 · Cited by 12
Gobeil, P., Pillet, S., Boulay, I., Charland, N., Lorin, A., Cheng, M. P., Vinh, D. C., Boutet, P., der Most, R. G. V., Roman, F. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34728-1 · Cited by 13
Towards a unified approach in managing resistance to vaccines, drugs, and pesticides
Alyokhin, A., Rosenthal, B. M., Weber, D. C., & Baker, M. B. (2025) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.13174 · Cited by 11
Herrera, B. B., Chaplin, B., Mboup, S., Abdullahi, A., He, M., Fisher, S. M., Akanmu, S. A., Chang, C. A., Hamel, D. J., Gupta, R. K., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1522733 · Cited by 12
Why are there so few (or so many) circulating coronaviruses?
Rice, B. L., Douek, D. C., McDermott, A. B., Grenfell, B. T., & Metcalf, C. J. E. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.07.001 · Cited by 11
Khanolkar, A. (2021) · Cells · doi:10.3390/cells11010067 · Cited by 12
Olafsdottir, T. A., Bjarnadóttir, K., Norddahl, G. L., Halldorsson, G. H., Melsted, P., Gunnarsdóttir, K., Ivarsdottir, E. V., Ólafsdóttir, Þ., Arnthorsson, A. O., Theódórs, F., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03893-w · Cited by 10
Zhao, J., Xu, X., Gao, Y., Yu, Y., & Li, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814133 · Cited by 11
McNaughton, A. L., Paton, R. S., Edmans, M. D., Youngs, J., Wellens, J., Phalora, P. K., Fyfe, A. J., Belij‐Rammerstorfer, S., Bolton, J. S., Ball, J., et al. (2021) · medRxiv · doi:10.1101/2021.05.04.21256571 · Cited by 11
The Recent Updates on Approaches and Clinical Trials Status of Covid-19 Vaccines Developed Globally
Chaudhary, S., El‐Shorbagi, A., Gupta, R. K., & Kumar, A. (2021) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2214 · Cited by 11
Costa, C. S., Scozzari, G., Migliore, E., Galassi, C., Ciccone, G., Ricciardelli, G., Scarmozzino, A., Angelone, L., Cassoni, P., Cavallo, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10071031 · Cited by 11
Luo, M., Zhou, B., Reddem, E. R., Tang, B., Chen, B., Zhou, R., Liu, H., Liu, L., Katsamba, P. S., Au, K., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2146538 · Cited by 11
Barie, P. S., Ho, V. P., Hunter, C. J., Kaufman, E. J., Narayan, M., Pieracci, F. M., Schubl, S. D., Heffernan, D. S., & Huston, J. M. (2021) · Surgical Infections · doi:10.1089/sur.2020.421 · Cited by 11
Patel, R. S., & Agrawal, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952229 · Cited by 10
Characteristics and Roles of T Follicular Helper Cells in SARS-CoV-2 Vaccine Response
Chi, X., Gu, J., & Ma, X. (2022) · Vaccines · doi:10.3390/vaccines10101623 · Cited by 9
Francis, M. E., Jansen, E. B., Yourkowski, A., Selim, A., Swan, C. L., MacPhee, B. K., Thivierge, B. M., Buchanan, R. M., Lavender, K. J., Darbellay, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41761-1 · Cited by 11
COVID-19 related interdisciplinary methods: Preventing errors and detecting research opportunities
Rivas, A. L., & Regenmortel, M. H. V. V. (2021) · Methods · doi:10.1016/j.ymeth.2021.05.014 · Cited by 10
Zhao, J., Zhu, J., Huang, C., Zhu, X., Zhu, Z., Wu, Q., & Yuan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035151 · Cited by 9
Lockdown Effects on Sars-CoV-2 Transmission – The evidence from Northern JutlandPreprint
Kepp, K. P., & Bjørnskov, C. (2021) · medRxiv · doi:10.1101/2020.12.28.20248936 · Cited by 12
Stepanova, E., Matyushenko, V., Mezhenskaya, D. А., Bazhenova, E. A., Kotomina, T. S., Rak, A. Y., Donina, S., Chistyakova, A. K., Kostromitina, A. D., Novitskaya, V., et al. (2024) · Vaccines · doi:10.3390/vaccines12121300 · Cited by 7
Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity
He, Q., Zhang, Y., Fu, Z., Ma, X., & Liang, Z. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2538561 · Cited by 8
A phenomenological estimate of the true scale of CoViD-19 from primary data
Palatella, L., Vanni, F., & Lambert, D. (2021) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2021.110854 · Cited by 7
N’Guessan, A., Kailasam, S., Mostefai, F., Poujol, R., Grenier, J., Ismailova, N., Contini, P., Palma, R. D., Haber, C., Stadler, V., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107394 · Cited by 9
Fedele, G., Schiavoni, I., Trentini, F., Leone, P., Olivetta, E., Fallucca, A., Fiore, S., Martino, A. D., Abrignani, S., Baldo, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272119 · Cited by 7
H-Vázquez, J., Cal‐Sabater, P., Arribas‐Rodríguez, E., Fiz‐López, A., Perez-Segurado, C., Martín‐Muñoz, Á., Prado, Á. D., Graciani, I. D. L. F., González, S. P., Gutiérrez, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1405217 · Cited by 8
Sun, H., Lü, Z., Xuan, G., Liu, N., Wang, T., Liu, Y., Lan, M., Xu, J., Feng, Y., Xu, S., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.671694 · Cited by 9
Immunomodulation and immunotherapeutics of COVID-19
Garg, S. S., Sharma, A., & Gupta, J. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108842 · Cited by 8
Spatio-Temporal Modeling of Immune Response to SARS-CoV-2 Infection
Alzahrani, T. A. (2021) · Mathematics · doi:10.3390/math9243274 · Cited by 8
Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines
Park, H., Park, M. S., Seok, J. H., You, J., Kim, J., Kim, J., & Park, M. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1598-x · Cited by 8
Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity
Pacheco-García, U., & Serafín‐López, J. (2023) · Vaccines · doi:10.3390/vaccines11030655 · Cited by 8
Lin, P., Liang, C.-Y., Yao, B., Chen, H., Pan, C.-F., Wu, L., Lin, Y.-H., Hsu, Y.-S., Liu, Y.-H., Chen, P., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.010 · Cited by 8
Is Symptom Screening Useful for Identifying COVID-19 Infection in School Settings? Georgia, USA
Swanson, M. R., Hast, M. A., Burnett, E., Oraka, E., Kimball, A. A., Morris, E., Marcet, P. L., Almendares, O. M., Franklin, R., Mehari, L., et al. (2021) · The Journal of School Nursing · doi:10.1177/10598405211050393 · Cited by 8
EpiCurator: an immunoinformatic workflow to predict and prioritize SARS-CoV-2 epitopes
Ferreira, C. D. S., Martins, Y., Souza, R. C., & de Vasconcelos, A. T. R. (2021) · PeerJ · doi:10.7717/peerj.12548 · Cited by 7
Bhuiyan, T. R., Banna, H. A., Kaisar, M. H., Karmakar, P. C., Hakim, A., Akter, A., Ahmed, T., Tauheed, I., Islam, S., Hasnat, M. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929849 · Cited by 6
Self-citationLani, R., Senin, N. A., AbuBakar, S., & Hassandarvish, P. (2022) · Vaccines · doi:10.3390/vaccines10101606 · Cited by 6
Martín-Galiano, A. J., Díez‐Fuertes, F., McConnell, M. J., & López, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.732693 · Cited by 7
The Differentiation and Maintenance of SARS-CoV-2-Specific Follicular Helper T Cells
Wang, Y., Qin, T., & Ye, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.953022 · Cited by 7
Borena, W., Kimpel, J., Gierer, M., Rössler, A., Riepler, L., Oehler, S., von Laer, D., & Miholits, M. (2021) · Vaccines · doi:10.3390/vaccines9060611 · Cited by 6
Evolution of SARS-CoV-2-specific CD4+ T cell epitopes
Brand, M., & Keşmir, C. (2023) · Immunogenetics · doi:10.1007/s00251-023-01295-8 · Cited by 7
Zhou, J., Uddback, I. E. M., Kohlmeier, J. E., Christensen, J. P., & Thomsen, A. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1322536 · Cited by 6
Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-γ ELISpot
Thümmler, L., Schwarzkopf, S., Knop, D., Ross, J. A., Berg, V., Horn, P. A., & Lindemann, M. (2021) · Diagnostics · doi:10.3390/diagnostics11081439 · Cited by 6
Sengupta, S., Bhattacharya, G., Chatterjee, S., Datey, A., Shaw, S. K., Suranjika, S., Nath, P., Barik, P. K., Prasad, P., Chattopadhyay, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848335 · Cited by 4
Immune Response to COVID-19 in India through Vaccination and Natural Infection
Sarraf, T. R., Maity, S., Ghosh, A. K., Bhattacharjee, S., Pani, A., Saha, K., Chattopadhyay, D., Ghosh, G., & Sen, M. (2022) · Fortune Journal of Health Sciences · doi:10.26502/fjhs.070 · Cited by 6
Chen, Y., Hu, C., Wang, Z., Su, J., Wang, S., Li, B., Liu, X., Yuan, Z., Li, D., Wang, H., et al. (2023) · Pathogens · doi:10.3390/pathogens12101254 · Cited by 4
Influenza A H1N1–mediated pre-existing immunity to SARS-CoV-2 predicts COVID-19 outbreak dynamicsPreprint
Almazán, N. M., Rahbar, A., Carlsson, M., Hoffman, T., Kolstad, L., Rönnberg, B. J., Pantalone, M. R., Lewensohn‐Fuchs, I., Nauclér, A., Ohlin, M., et al. (2021) · medRxiv · doi:10.1101/2021.12.23.21268321 · Cited by 6
Long- and short-term effects of cross-immunity in epidemic dynamics
Atienza-Diez, I., & Seoane, L. F. (2023) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2023.113800 · Cited by 5
Antigen-specific T cell responses in SARS-CoV-2 mRNA-vaccinated children
Philpott, J. D., Miller, J. D., Boribong, B. P., Charles, S., Davis, J. P., Kazimierczyk, S., Jimena, B., Leonard, M. M., Shreffler, W. G., Fasano, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101298 · Cited by 8
Impact of cross-reactivity and herd immunity on SARS-CoV-2 pandemic severity
Owusu‐Boaitey, N., Böttcher, L., He, D., Erkhembayar, R., Yang, L., Kim, D.-H., Барчук, А. А., Gorski, D. H., & Howard, J. (2024) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2024.2388222 · Cited by 5
Rooyen, C. V., Brauer, M., Swanepoel, P., van den Berg, S., van der Merwe, C., van der Merwe, M., Green, R. J., & Becker, P. (2022) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207556 · Cited by 5
Ma, Y., Liu, F., Lin, T., Chen, L., Jiang, A., Tian, G., Nielsen, M., & Wang, M. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab324 · Cited by 5
COVID-19: Is herd immunity the only option for fragile Yemen?
Noushad, M., & Al-Saqqaf, I. S. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.03.030 · Cited by 5
Ssemaganda, A., Nguyen, H. M., Nuhu, F., Jahan, N., Card, C. M., Kiazyk, S. A. K., Severini, G., Keynan, Y., Su, R., Ji, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.07.442971 · Cited by 5
Goliwas, K. F., Wood, A. M., Simmons, C. S., Khan, R., Khan, S. A., Wang, Y., Berry, J. L., Athar, M., Mobley, J. A., Kim, Y., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21263042 · Cited by 6
The COVID-19 pandemic in sub-Saharan Africa: The significance of presumed immune sufficiency
Idowu, A. O., Omosun, Y., Igietseme, J. U., & Azenabor, A. A. (2023) · African Journal of Laboratory Medicine · doi:10.4102/ajlm.v12i1.1964 · Cited by 3
Reiter, L., Greffrath, J., Zidel, B., Ostrowski, M., Gommerman, J. L., Madhi, S. A., Tran, R., Martín‐Orozco, N., Panicker, R. K. G., Cooper, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55320-1 · Cited by 5
Time-dependent contraction of the SARS-CoV-2–specific T-cell responses in convalescent individuals
Fernandes, E. R., Apostólico, J. D. S., Jacintho, L. C., Marin, M. L. C., Júnior, R. C. V. D. S., Rodrigues, H., Santos, K. S., Coelho, V. P. C. V., Boscardin, S. B., Kalil, J. E., et al. (2022) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2022.05.002 · Cited by 4
Chakrabarti, S., Chakrabarti, S. S., Kaur, U., Agrawal, B. K., Ganguly, U., & Jin, K. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26958 · Cited by 4
Partial remission of advanced untreated Sézary syndrome after COVID-19
Snowden, C. K., Ng, S., & Choi, J. (2022) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.12.005 · Cited by 4
Tolerance of Human Fibroblasts to Benfo-Oxythiamine In Vitro
Yan, M., Smeets, R., Gosau, M., Vollkommer, T., Fuest, S., Stetzer, E., Kluwe, L., Coy, J., & Burg, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074112 · Cited by 4
Pustake, M. V., Giri, P., Ganiyani, M. A., & Deshmukh, K. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2372_21 · Cited by 4
Mischke, J., Klein, S., Seamann, A., Prinz, I., Selin, L. K., Ghersi, D., Cornberg, M., & Kraft, A. R. M. (2022) · Viruses · doi:10.3390/v14102293 · Cited by 4
Murdocca, M., Citro, G., Centanini, E., Giannini, R., Latini, A., Centofanti, F., Mortari, E. P., Cocciadiferro, D., Novelli, A., Bernardini, S., et al. (2023) · Viruses · doi:10.3390/v15071417 · Cited by 4
Shen, X., Wang, S., Hao, Y., Fu, Y., Ren, L., Li, D., Tang, W., Li, J., Chen, R., Zhu, M., et al. (2024) · Virologica Sinica · doi:10.1016/j.virs.2024.05.005 · Cited by 4
Kovačić, D., Gajić, A. A., Latinović, D., & Softić, A. (2021) · Journal of Medical Science · doi:10.20883/medical.e551 · Cited by 4
Paniskaki, K., Anft, M., Thieme, C. J., Skrzypczyk, S., Konik, M., Dolff, S., Westhoff, T. H., Nienen, M., Stittrich, A., Stervbo, U., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.02.016 · Cited by 4
How Will the Covid-19 Vaccines Help Shape the Herd Immunity against Covid-19?
Weitao, T. (2021) · Virology & Immunology Journal · doi:10.23880/vij-16000264 · Cited by 3
COVID-19 in a case previously infected with MERS-CoV: No cross immunity
Al-Maani, A. S., Al‐Jardani, A., Karrar, H., Petersen, E., & Abri, S. A. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.11.035 · Cited by 4
McNaughton, A. L., Paton, R. S., Edmans, M. D., Youngs, J., Wellens, J., Phalora, P. K., Fyfe, A. J., Belij‐Rammerstorfer, S., Bolton, J. S., Ball, J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3858917 · Cited by 4
The Influence of Time on the Sensitivity of SARS-CoV-2 Serological TestingPreprint
Ortiz, A. T., Torrente, F. F., Twigg, A., Hatcher, J., Saso, A., Lam, T., Johnson, M., Wagstaffe, H. R., Dhillon, R., Mai, A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1286644/v1 · Cited by 4
Heterologous immunity and antibody-dependent enhancement in respiratory virus infections
Isamuddin, N. H. N., AbuBakar, S., Chin, K.-L., & Zainal, N. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11189-5 · Cited by 3
Jose, D., Dhupdale, N. Y., Cacodcar, J. A., & Kamat, U. S. (2022) · Current Drug Safety · doi:10.2174/1574886317666220803104438 · Cited by 3
Potential Usefulness of IgA for the Early Detection of SARS-CoV-2 Infection: Comparison With IgM
Wang, P. (2024) · Polish Journal of Microbiology · doi:10.33073/pjm-2024-019 · Cited by 3
Insights into the virologic and immunologic features of SARS-COV-2
Polat, C., & Ergünay, K. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i19.5007 · Cited by 3
Metadata
- Authors
- Lipsitch, M., Grad, Y. H., Sette, A., & Crotty, S.
- Affiliations
- Harvard University (US)
- La Jolla Institute for Immunology (US)
- Corresponding author
- Lipsitch, Marc
- Grad, Yonatan H.
- Sette, Alessandro
- Crotty, Shane
- Venue
- Nature Reviews Immunology
- Published
- 2020-10-06
- Volume
- 20
- Issue
- 11
- Pages
- 709-713
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7537578
- OpenAlex
- W3091791643
- Cited by
- 260
- References
- 48
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 12 · 2023: 29 · 2022: 59 · 2021: 129 · 2020: 9
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (75N9301900065)
- National Institute of Allergy and Infectious Diseases (U19 AI42742, 75N9301900065, AI42742, U19AI142742)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2, cross-reactive T cells, memory CD4+ T cells, herd immunity threshold, COVID-19 severity, common cold coronaviruses, pre-existing immunity, virus transmission, epidemic modeling, COVID-19 pandemic
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Antibodies, Viral, Coronaviridae, Coronaviridae Infections, Cross Reactions, Humans, Immunologic Memory, Pneumonia, Viral, Rhinovirus, Viral Vaccines, CD4-Positive T-Lymphocytes, Coronavirus Infections, Immunity, Herd, Adaptive Immunity, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
